Ensign Declares Quarterly Dividend of $0.0575 Per Share

Ensign Declares Quarterly Dividend of $0.0575 Per Share

June 16, 2023 | Last Trade: US$134.59 0.53 -0.39

SAN JUAN CAPISTRANO, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign^TM group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.0575 per share of Ensign common stock, payable on or before July 31, 2023, to shareholders of record as of June 30, 2023.

Ensign has been a dividend-paying company since 2002.

About Ensign ^™

The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 290 healthcare facilities, in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information

The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$134.59
Daily Change:	-0.53 -0.39
Daily Volume:	833,968
Market Cap:	US$7.710B

December 18, 2024 Ensign Agrees to Add Its First Operations in Alaska and Oregon And Announces Expansion in Washington and California November 13, 2024 Ensign to Present at the Stephens Annual Investment Conference on November 20, 2024 November 04, 2024 Ensign Acquires Facilities in Wisconsin October 29, 2024 Ensign Announces Expansion in Tennessee, Agrees to Add Its First Operation in Alabama October 24, 2024 Ensign Reports Third Quarter 2024 Results; Raises Annual Earnings and Revenue Guidance LOAD MORE NEWS

Featured Stock

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE